Related Experiment Video
Updated: Jun 25, 2026
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
JAK2V617F mutations in myeloid malignancies: single center experience
Irina Panovska-Stavridis1, L Cevreska, M Ivanovski
1Clinic of Hematology, Faculty of Medicine, University Ss. Cyril and Methodius Skopje, Skopje, Republic of Macedonia. dr_irina@yahoo.com
Prilozi
|March 5, 2009
Summary
The JAK2V617F mutation is a key marker for myeloproliferative neoplasms (MPNs), aiding diagnosis. Patients with this mutation show a higher incidence of thrombotic complications.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- The JAK2 V617F mutation is a significant diagnostic marker for myeloproliferative neoplasms (MPNs).
- Understanding its role in MPN pathogenesis and clinical outcomes is crucial.
Purpose of the Study:
- To investigate the frequency of JAK2 V617F mutations in MPN and acute myeloid leukemia (AML) patients.
- To analyze the association between JAK2 V617F mutations and clinical features in MPN patients.
Main Methods:
- Screening of 192 patients with MPN and AML for JAK2 V617F mutations.
- Utilizing allele-specific PCR assay for mutation frequency analysis.
- Correlating mutation status with clinical features and prognosis.
Main Results:
- JAK2 V617F mutation detected in 65.3% of MPN cases (100/153).
- No JAK2 V617F mutation found in 39 AML cases.
- MPN patients with the mutation had a significantly higher incidence of thrombotic complications (38.5% vs 19.2%).
Conclusions:
- JAK2 V617F mutation holds diagnostic significance in MPNs.
- The mutation is associated with an increased risk of thrombosis in MPN patients.
- Findings support classifying JAK2 V617F-positive MPNs as a distinct entity.
Related Concept Videos
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...